Federal Laboratory Consortium for Technology Transfer

Moving Federal Laboratory Innovations Into International Markets

A federal laboratory technology can offer a foreign company a valuable path to new products, manufacturing methods, software, materials, or scientific services. The opportunity may begin with a patent, prototype, dataset, biological material, or specialized process developed through U.S. government research. Commercial interest, however, does not automatically create a right to use or export that technology.

The transfer process connects technical fit, intellectual property, national security review, export compliance, and business planning. A company must identify the right laboratory and agency, determine what rights are available, and show that it can commercialize the invention responsibly in the intended markets.

Federal technology transfer offices and the Federal Laboratory Consortium help make that path easier to navigate. The consortium connects businesses and researchers with more than 300 federal laboratories, available technologies, and laboratory experts across seven regional areas. Its resources can help an international company move from a broad concept to a credible licensing discussion.

Find The Right Federal Technology

The search begins with a clear commercial problem rather than a general request for “new technology.” Define the performance target, industry, technical specifications, target countries, regulatory environment, and preferred stage of development. A company seeking a corrosion-resistant coating will need a different laboratory contact and evaluation plan from a company looking for cybersecurity software or medical diagnostics.

The FLC technology locator and available technology listings can reveal inventions that are already being offered for licensing. A laboratory directory can also identify scientists with relevant expertise when a listed invention does not fully match the company’s needs. This guide to finding experts explains how to use the directory to locate useful technical contacts without treating the search as a simple product catalog.

A foreign company should also identify the federal agency that owns or controls the relevant intellectual property. The laboratory that performed the research may manage the invention, while an agency headquarters office, technology transfer office, or contracting organization handles the agreement. Ownership records, patent status, software rights, and material-transfer restrictions should be confirmed before serious commercial planning begins.

Establish Access And Confidentiality

After identifying a promising technology, the company usually contacts the laboratory’s technology transfer office. The first discussion may cover the invention’s technical maturity, existing patent applications, licensing status, laboratory capabilities, and possible evaluation arrangements. A concise company profile and a specific use case make it easier for federal staff to determine whether the opportunity is suitable.

Confidential information requires particular care. Federal employees and technology transfer personnel may be able to discuss public descriptions, but unpublished technical details generally require an appropriate confidentiality agreement. A nondisclosure agreement should identify what can be shared, who may receive it, how long confidentiality lasts, and whether the company’s foreign affiliates, consultants, or investors may access the information.

Some federal laboratories use an evaluation license, material transfer agreement, or other limited-purpose instrument before negotiating a commercial license. These agreements can govern access to prototypes, samples, software, test data, or laboratory assistance. They may prohibit reverse engineering, redistribution, foreign retransfer, or use outside a defined evaluation. Signing one does not necessarily grant production or sales rights.

Select The Transfer Mechanism

The appropriate legal instrument depends on the asset and the intended relationship. A patent license may authorize production, use, sale, or importation of a patented invention. A copyright license may address software, technical documentation, or databases. A material transfer agreement may permit testing of a biological or physical sample, while a cooperative research and development agreement can support joint work between a federal laboratory and a nonfederal partner.

Federal laboratories generally distinguish between access to technical knowledge and rights to commercialize an invention. A scientist may explain a published method or discuss laboratory capabilities, but those conversations do not replace a license. The company should ask which rights are available, whether the license can cover foreign territories, and whether rights are exclusive, partially exclusive, or nonexclusive.

The agreement may also address field of use, term, sublicensing, milestones, royalties, patent prosecution, reporting, quality controls, government-use rights, and termination. A foreign company should examine whether the license permits manufacture in its home country, distribution through affiliates, sales into the United States, and sublicensing to local partners.

Transfer instrument Common purpose Important issues for a foreign company
Patent or patent-pending license Commercial use of an invention Territory, field of use, patent status, royalties, manufacturing obligations
Software or copyright license Use, modification, or distribution of software and technical materials Source-code access, redistribution, cybersecurity, open-source components
Material transfer agreement Evaluation of samples, compounds, organisms, or prototypes Permitted experiments, biosafety, retransfer, destruction or return
CRADA Collaborative research and development with a federal laboratory Cost sharing, data rights, inventions, publication, export controls
Technical assistance or testing arrangement Access to laboratory expertise, equipment, or validation Scope of work, confidentiality, deliverables, personnel access

Address U.S. Policy And Export Rules

Federal technology transfer is shaped by public-interest requirements. An exclusive license may require substantial U.S. manufacturing or other domestic production commitments, depending on the agency, technology, and statutory authority. A foreign company seeking broad exclusivity should be prepared to describe its U.S. manufacturing plans, supply chain, investment, employment impact, or rationale for requesting a waiver.

The company must also determine whether the technology is subject to the Export Administration Regulations, International Traffic in Arms Regulations, nuclear-related controls, sanctions, or agency-specific restrictions. Export controls can apply to technical data, software, equipment, and services—not only to physical shipments. A transfer to a foreign parent, employee, contractor, or affiliate may be treated as an export even when the material remains inside the United States.

Classification should occur early, before technical files are shared with overseas staff or incorporated into a global development platform. The laboratory or agency may provide information about known controls, but the company remains responsible for building an effective compliance program. This may involve screening parties, controlling access, obtaining licenses, documenting end uses, and preventing unauthorized reexports.

Certain information may be classified, export-controlled, personally identifiable, or otherwise restricted from ordinary commercial licensing. A technology that appears attractive in a public listing may therefore require a narrower scope, additional government approval, or a different project structure. Early legal and compliance review can prevent a business team from promising customers rights it cannot obtain.

Build A Commercialization Case

A federal laboratory will want evidence that the prospective partner can develop and deploy the technology. The company should prepare a commercialization plan covering technical validation, funding, manufacturing, regulatory approvals, target customers, distribution, and expected timing. It should explain what work will remain with the laboratory and what work the company will perform independently.

The plan should distinguish laboratory feasibility from market readiness. A prototype tested in a federal facility may need reliability testing, scale-up, cybersecurity hardening, clinical work, environmental review, or certification before sale. A realistic budget and milestone schedule help the parties decide whether a license, CRADA, paid testing agreement, or staged evaluation is the best starting point.

Foreign market access can be a strength, but it must be presented with precision. Identify the jurisdictions where the company has operating entities, manufacturing capacity, regulatory knowledge, and customer relationships. Also explain how U.S. sales, local content rules, data protection laws, and reexport restrictions will be handled.

Negotiations are usually more productive when the company proposes measurable milestones. These may include completion of a technical evaluation, submission of a regulatory application, first commercial production, minimum annual royalties, or a defined investment in development. Milestones give the government a way to assess progress and give the company a structured opportunity to reduce risk.

Negotiate And Execute The Agreement

A technology transfer office will coordinate the negotiation, but several specialists may participate. Patent counsel may review claims and prosecution strategy; export officials may evaluate controlled technology; laboratory scientists may define technical work; procurement or contracting personnel may address funding and liability; and agency counsel may approve the final terms.

The foreign company should review definitions carefully. “Affiliate,” “territory,” “commercial use,” “technical data,” and “sublicensee” can determine whether the business model is actually permitted. The agreement should also clarify ownership of improvements, treatment of jointly developed inventions, audit rights, royalty reports, indemnification, insurance, publication review, and dispute procedures.

Government rights remain an important feature of many federal licenses. The United States may retain rights for government purposes, and the agreement may include march-in, termination, or compliance provisions required by law or agency policy. These terms do not necessarily prevent commercial success, but they should be reflected in financing documents, investor disclosures, and customer commitments.

Before execution, the company should verify that its proposed signatory has authority, its corporate structure is accurately disclosed, and all required approvals are complete. A license becomes commercially useful only when its rights align with the company’s actual operations. If manufacturing, software development, or sales will involve several affiliates, each entity’s role should be addressed expressly.

Manage The Relationship After Signing

The transfer does not end when the agreement is executed. The company may need to submit royalty reports, milestone updates, patent notices, compliance certifications, and requests for consent before changing suppliers or sublicensing rights. Maintaining accurate records is especially important when products cross borders or rely on multiple affiliated entities.

Technical collaboration may continue through testing, troubleshooting, facility access, or a CRADA. The parties should establish named contacts, meeting schedules, data-transfer procedures, and a process for documenting new inventions. Clear separation between publicly releasable information and controlled or confidential information protects both the laboratory and the company.

A strong post-license program also monitors changes in law and business structure. A merger, new foreign investor, transfer of manufacturing, or addition of a distributor can affect export authorization and license compliance. The company should review these events before implementation rather than assuming that existing permissions automatically follow the new arrangement.

Businesses at the discovery stage can use the FLC’s request information service to identify relevant laboratories, technologies, and technology transfer contacts. Providing a focused description of the technical need, intended market, and desired partnership will produce a more useful starting point than sending a generic inquiry.

Prepare For A Responsible First Approach

A foreign company can make federal innovation a practical part of its international growth strategy when it treats the process as a structured partnership rather than a simple purchase. Begin with the relevant technology transfer office, present a credible commercialization case, and request guidance on the rights, controls, and agreement that fit the proposed use. The right early conversation can turn a federal laboratory discovery into a compliant, investable path toward products and services in global markets.